Litcius/Paper detail

Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori

Takahisa Furuta, Mihoko Yamade, Tomohiro Higuchi, Satoru Takahashi, Natsuki Ishida, Shinya Tani, Satoshi Tamura, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Ken Sugimoto

2023Journal of Clinical Medicine11 citationsDOIOpen Access PDF

Abstract

Vonoprazan (VPZ) inhibits gastric acid secretion more potently than proton pump inhibitors. Recently, attention has been focused on the dual therapy with VPZ and amoxicillin (AMOX) for the eradication of H. pylori. The dual VPZ/AMOX therapy attains the sufficient eradication rate with lowering the risk of adverse events in comparison with the triple therapy and quadruple therapy. Therefore, the dual VPZ/AMOX therapy is considered a useful eradication regimen for H. pylori infection.

Topics & Concepts

MedicineAmoxicillinRegimenInternal medicineDual (grammatical number)GastroenterologyAdverse effectHelicobacter pyloriCure rateMicrobiologyAntibioticsArtBiologyLiteratureHelicobacter pylori-related gastroenterology studiesMicrobial Metabolites in Food BiotechnologyGastroesophageal reflux and treatments
Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori | Litcius